Search

Displaying results 4811 - 4820 of 10000 in total
  1. Target

    Retinoic acid-induced protein 3

    go.drugbank.com/bio_entities/BE0000697
    TargetHumans

    Orphan receptor. Could be involved in modulating differentiation and maintaining homeostasis of epithelial cells.

    Synonyms: G protein-coupled receptor family C group 5 member A
  2. Target

    VLA-4 (very late antigen-4)

    go.drugbank.com/bio_entities/BE0010014
    TargetHumans

    Integrin alpha-4/beta-1 is a receptor for VCAM1. It recognizes the sequence Q-I-D-S in VCAM1. Integrin alpha-9/beta-1 is a receptor for VCAM1, cytotactin and osteopontin. … Integrin alpha-4/beta-7 is also a receptor for MADCAM1. It recognizes the sequence L-D-T in MADCAM1.

    Synonyms: Fibronectin receptor subunit beta
  3. Target

    NACHT, LRR and PYD domains-containing protein 3

    go.drugbank.com/bio_entities/BE0010347
    TargetHumans

    Sensor component of the NLRP3 inflammasome, which mediates inflammasome activation in response to defects in membrane integrity, leading to secretion of inflammatory cytokines IL1B and IL18 and pyroptosis (PubMed:16407889, PubMed:1840367...

    Synonyms: Angiotensin/vasopressin receptor AII/AVP-like
  4. Drug

    CYT006-AngQb

    go.drugbank.com/drugs/DB05739
    Investigational

    It is a unique treatment modality that aims to address the issue of patient compliance by offering convenient dosing schedules due to the long-lasting effect induced by vaccination. … It is designed to instruct the patient’s immune system to produce an antibody response against angiotensin II, a small peptide that causes blood vessels to narrow and results in increased blood pressure

  5. Drug

    Nedaplatin

    go.drugbank.com/drugs/DB13145
    ApprovedInvestigational

    Nedaplatin is a second generation platinum analog . It is less nephrotoxic than DB00515 but has proven equally effective. It was approved for use in Japan in 1995.

  6. Drug

    3,4-Methylenedioxy-N-isopropylamphetamine

    go.drugbank.com/drugs/DB06112
    Experimental

    MDI-P has been shown to be effective in killing HIV in cell culture. HIV is the virus that causes acquired immune deficiency syndrome (AIDS). … MDI-P is also a potential therapeutic agent for the treatment of the symptoms of cystic fibrosis ("CF").

  7. Drug

    Clioquinol

    go.drugbank.com/drugs/DB04815
    ApprovedVet approvedWithdrawn

    Clioquinol was withdrawn in 1983 due to neurotoxicity.

  8. Drug

    Tandutinib

    go.drugbank.com/drugs/DB05465
    Investigational

    MLN518 is a novel, oral, small molecule designed to inhibit type III receptor tyrosine kinases, including FLT3, (platelet-derived growth-factor receptor) PDGFR and c-KIT. … Approximately 25 to 30 percent of all adult AML patients have a mutation of the FLT3 gene. The use of MLN518 to treat AML has been granted fast-track status by the U.S. Food and Drug Administration.

  9. Drug

    Rilapladib

    go.drugbank.com/drugs/DB05119
    Investigational

    Rilapladib is the third genomics-derived small molecule drug arising from the Human Genome Sciences-GlaxoSmithKline collaboration to enter clinical development. … Lp-PLA2 is an enzyme associated with the formation of atherosclerotic plaques.

  10. Drug

    Allisartan isoproxil

    go.drugbank.com/drugs/DB18880
    Investigational

    Allisartan isoproxil is under investigation in clinical trial NCT03264352 (Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes).

    Categories: Agents Acting on the Renin-Angiotensin System, Angiotensin Receptor Antagonists